Tag:
Posidur
Latest Headlines
Latest Headlines
Durect's pain drug fails to clear key hurdle in PhIIb
Just days after signing a $212.5 million U.S. licensing deal with Hospira , Durect (DRRX) reports that its pain drug Posidur--a long-acting version of the anesthetic bupivacaine--equaled an injectable
